HOME / CONTACT US
繁體版 / 简体版
  • ABOUT COMPANY
    • History
    • Team
    • Collabration
    • Nanchou Plant
    • Expanded Access Program
  • SCIENCE
    • Pipeline & Therapeutic area
    • ON101
    • OB318
    • FB825
    • FB704A
    • FB918
    • SNS01
    • Technology
  • INVESTOR
    • Corporate Governance
    • Financials
    • Shareholders’ Meeting
    • Corporate Presentation
    • Investor FAQs
  • NEWS
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
  • CSR
    • Human rights policy
  • CAREERS
    • Careers
    • Join us
  • ABOUT COMPANY
    • History
    • Team
    • Collabration
    • Nanchou Plant
    • Expanded Access Program
  • SCIENCE
    • Pipeline & Therapeutic area
    • ON101
    • OB318
    • FB825
    • FB704A
    • FB918
    • SNS01
    • Technology
  • INVESTOR
    • Corporate Governance
      • Governance Structure Shareholding Structure Board of Directors Audit Committee Compensation Committee Internal Audit Major Internal Policies
    • Financials
      • Financial Report / Financial Statements Stock Quotes
    • Shareholders’ Meeting
      • Annual Report Meeting Minutes / Meeting Agenda Meeting Notice
    • Corporate Presentation
      • Events and Presentations
    • Investor FAQs
      • CONTACT US FAQs(category)
    • ABOUT COMPANY
      • History Team Collabration Nanchou Plant Expanded Access Program
    • SCIENCE
      • Pipeline & Therapeutic area ON101 OB318 FB825 FB704A FB918 SNS01 Technology
    • CSR
      • Human rights policy
    • Careers
      • Careers Join us
  • NEWS
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
  • CAREERS
    • Careers
    • Join us
  • CONTACT US
  • 繁體版
  • 简体版
 
 
NEWS
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017

NEWS

 

Title Date
Oneness Biotech invited for oral presentation at the 36th Healthcare Conference organized by J.P. Morgan 2017-12-27
Oneness Biotech filed the second Phase 3 IND of ON101 to FDA. 2017-11-21
Oneness Biotech has licensed out ON101, a novel drug for treating diabetic foot ulcer to Microbio Shanghai for co-development and commercialization in mainland China, Hong Kong and Macao. 2017-11-10
Oneness Biotech has licensed out OB318, a novel drug candidate for hepatocellular carcinoma to Microbio Shanghai for co-development and commercialization in mainland China, Hong Kong and Macao. 2017-11-10
The multinational phase III clinical trial of ON101 has been greenlighted by CFDA 2017-07-18


Copyright © Oneness Biotech Co., Ltd. All Rights Reserved.